Retrovir (Zidovudine, AZT)

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Retrovir (Zidovudine, AZT)

The Basics | News | Research | Archive

See also: Drug Interactions | Medication Side Effects

Brand Name:	Retrovir
Generic Name:	Zidovudine, AZT
Adult Single Dose:	One 300-mg tablet (twice a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Retrovir (Zidovudine, AZT) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Zidovudine (Retrovir, AZT) (September 30, 2008)
To read PDF, click here
From AIDS InfoNet
Retrovir (Zidovudine, ZDV, AZT) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
AZT (Retrovir, Zidovudine, ZDV) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Patient Information About Retrovir (Zidovudine, AZT) Oral Solution (PDF) (November 2006)
From GlaxoSmithKline
AZT (Zidovudine, Retrovir) (October 19, 2006)
From AIDS Treatment Data Network
AZT (zidovudine, Retrovir) (October 19, 2006)
From AIDS Treatment Data Network
Patient Information About Retrovir (Zidovudine, AZT) IV Infusion (PDF) (October 2006)
From GlaxoSmithKline
Retrovir (Zidovudine) (November 2005)
To read PDF, click here
From The Center for AIDS
Approval of Generic Zidovudine (September 20, 2005)
From U.S. Food and Drug Administration
Drug Interactions: Zidovudine (August 2004)
From Project Inform

News

GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
Program reduces out-of-pocket expense burden for eligible patients on GSK HIV medications.
From GlaxoSmithKline
FDA Approves First Generic HIV/AIDS Drug in Capsule Form for United States Market (March 31, 2006)
From U.S. Food and Drug Administration
A Bitter-Sweet Pill (March 2006)
The first ever HIV drug, AZT, has a checkered history. What's next for the drug as it comes off patent in the UK?.
From Positive Nation
FDA Approves Four Generic Forms of Zidovudine for U.S. Sales After Retrovir's Patent Expires (September 21, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon (September 20, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Zidovudine Generic Oral Solution Approved in United States (September 20, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Aurobindo Receives Tentative FDA Approval to Produce Generic Pediatric Version of AZT (Retrovir) for PEPFAR (September 12, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
FDA Grants Tentative Approval for First Generic Version of AZT for Use in Developing World (July 15, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Chinese Government Approves Sale of a Domestic AIDS Drug (August 13, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Simplified AZT Regimen Cuts Maternal-Infant Transmission in Half (March 6, 1998)
In AIDS Treatment News, from AIDS Treatment News
The Problem With AZT (Spring 1998)
In Women Alive Newsletter, from Women Alive
AZT in New Strength (Spring 1997)
In Women Alive Newsletter, from Women Alive
Dethroning AZT (February 1997)
In GMHC Treatment Issues, from Gay Men's Health Crisis

Research

Studies Raise Possible Long-Term Concern for Infants Exposed to Retrovir in Womb (April 16, 2007)
From aidsmap.com
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
HIV-Positive Mothers Should Continue AZT Prophylaxis After Childbirth, Study Says (October 3, 2004)
A study finds a brief jump in breast milk viral load following AZT cessation.
From aidsmap.com
Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
No PK Interaction Seen Between FTC and AZT or Tenofovir (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Nevirapine Reduced Mother-to-Child Transmission Better Than AZT -- At 70 Times Less Cost (September 12, 2003)
In AIDS Treatment News, from AIDS Treatment News
Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Thai Hospital Claims Reduced Mother-Baby Transmission (July 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
Pharmacodynamic Effects of Zidovudine 600 mg Once Daily Versus Zidovudine 300 mg Twice Daily in Therapy-Naive HIV-Infected Patients (COD20002) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
New Zidovudine-Resistant HIV Found in Treatment-Naive Patients (December 2001)
In HEPP News, from Brown Medical School
Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
AZT and d4T Cross-Resistance (August 8, 2000)
In STEP Ezine, from Seattle Treatment Education Project
Two Studies Shed Light on Development of d4T Resistance (July 13, 2000)
In The XIII International AIDS Conference, from The Body PRO
Reassuring Findings About Infants Exposed to Zidovudine (January 12, 1999)
From U.S. National Institute of Allergy and Infectious Diseases
Perinatal HIV-1 Transmission: Interaction between Zidovudine Prevention and Mode of Delivery in the French Perinatal Cohort (June 27, 1998)
In The 12th International AIDS Conference, from The Body PRO
A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm³ (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm³ (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Should AZT and d4T Be Used Together? (February 2, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Important Information on the Combination of Zidovudine (ZDV) and Stavudine (d4T) in ZDV-Experienced HIV-Infected Patients (November 22, 1996)
From International Association of Physicians in AIDS Care

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.